Cipla Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CIPLA, and when can generic versions of CIPLA drugs launch?
CIPLA has ninety-two approved drugs.
There are six US patents protecting CIPLA drugs. There are thirty-three tentative approvals on CIPLA drugs.
There are thirty patent family members on CIPLA drugs in twenty-one countries and four hundred and thirty-nine supplementary protection certificates in seventeen countries.
Summary for Cipla
| International Patents: | 30 |
| US Patents: | 6 |
| Tradenames: | 81 |
| Ingredients: | 81 |
| NDAs: | 92 |
| Patent Litigation for Cipla: | See patent lawsuits for Cipla |
| PTAB Cases with Cipla as petitioner: | See PTAB cases with Cipla as petitioner |
Drugs and US Patents for Cipla
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cipla | DEFERASIROX | deferasirox | GRANULE;ORAL | 215026-001 | Feb 23, 2022 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
| Cipla Ltd | CARBOPLATIN | carboplatin | INJECTABLE;INJECTION | 077383-002 | Jan 27, 2006 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| Cipla | CASPOFUNGIN ACETATE | caspofungin acetate | POWDER;INTRAVENOUS | 209489-002 | Jul 12, 2018 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cipla Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hungary | E030523 | ⤷ Try a Trial |
| Australia | 2008326297 | ⤷ Try a Trial |
| South Korea | 20100110297 | ⤷ Try a Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Cipla Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2563920 | CR 2019 00001 | Denmark | ⤷ Try a Trial | PRODUCT NAME: INOTERSEN AND SALT THEREOF, INCLUDING SODIUM SALTS; REG. NO/DATE: EU/1/18/1296 20180710 |
| 0443983 | C00443983/03 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| 2435024 | 21C1020 | France | ⤷ Try a Trial | PRODUCT NAME: COMBINAISON DE FORMOTEROL (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI), GLYCOPYRROLATE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI) ET BUDESONIDE (Y COMPRIS LES SELS, ESTERS, SOLVATES OU ENANTIOMERES PHARMACEUTIQUEMENT ACCEPTABLES DE CELUI-CI); REGISTRATION NO/DATE: EU/1/20/1498 20201210 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
